Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
| العنوان: | Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1? |
|---|---|
| المؤلفون: | Yaxiong Zhang, Huaqiang Zhou, Li Zhang |
| المصدر: | Journal for Immunotherapy of Cancer Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-4 (2018) |
| بيانات النشر: | BioMed Central, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Male, Cancer Research, Lung Neoplasms, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Pembrolizumab, NSCLC, Anti-PD-L1, B7-H1 Antigen, Carboplatin, Squamous, 0302 clinical medicine, Antineoplastic Agents, Immunological, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Immunology and Allergy, Medicine, Atezolizumab, Aged, 80 and over, Hazard ratio, Antibodies, Monoclonal, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Anti-PD-1, 030220 oncology & carcinogenesis, Molecular Medicine, Female, Immunotherapy, Adult, medicine.medical_specialty, Paclitaxel, Immunology, Antibodies, Monoclonal, Humanized, lcsh:RC254-282, 03 medical and health sciences, Young Adult, Internal medicine, Humans, Lung cancer, Adverse effect, Aged, Pharmacology, Chemotherapy, business.industry, medicine.disease, Confidence interval, 030104 developmental biology, Commentary, business |
| الوصف: | Recent randomized phase III trials (KEYNOTE-407 and IMpower131) reported that adding anti-programmed death (ligand) 1 (anti-PD-(L)1) antibodies in combination with taxane-platinum improve the therapeutic efficacy for advanced squamous non-small-cell lung cancer (NSCLC). However, there is no head-to-head comparison of pembrolizumab (anti-PD-1) plus chemotherapy vs. atezolizumab (anti-PD-L1) plus chemotherapy. Therefore, we performed an indirect comparison to explore the optimal choice of anti-PD-(L)1 treatment for advanced squamous NSCLC in combination with chemotherapy. The clinical outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and adverse event (AE). For overall patients, pembrolizumab had significantly superior OS (hazard ratio (HR) with 95% confidence interval, 0.67, 0.47–0.94; P = 0.02) and numerically better PFS (HR, 0.79, 0.60–1.04; P = 0.10) than atezolizumab, while they had similar ORR, all cause AE and grade 3–5 AE. For PD-L1 high patients, pembrolizumab and atezolizumab showed similar OS and PFS. However, for PD-L1 low/negative patients, pembrolizumab had superior OS (HR, 0.43, 0.24–0.76; P |
| اللغة: | English |
| تدمد: | 2051-1426 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2adfcb3d2075f280dbefe576a78b0a22Test http://europepmc.org/articles/PMC6276157Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....2adfcb3d2075f280dbefe576a78b0a22 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20511426 |
|---|